Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Data Mining HeData Mining Helps Detect Adverse Drug Reactions

By BiotechDaily International staff writers
Posted on 18 Jun 2013
A new study suggests that information held in electronic medical records (EMRs) can validate previously reported adverse drug reactions (ADRs) and report new ones.

Researchers at the New Jersey Institute of Technology (NJIT; Newark, USA) examined 12 years of EMR data from Vanderbilt University Medical Center (VUMC; Nashville, TN, USA; www.mc.vanderbilt.edu) and reviewed retrospective medication orders and inpatient laboratory results documented in the EMR to identify ADRs. The researchers then assessed the relative merits of six pharmacovigilance measures used in spontaneous reporting systems: proportional reporting ratio (PRR), reporting OR (ROR), Yule's Q (YULE), the CHI-squared test, Bayesian confidence propagation neural networks (BCPNN), and a gamma Poisson shrinker (GPS).

The researchers then systematically evaluated the six methods on two independently constructed reference standard datasets of drug-event pairs. The first was the Yoon et al dataset, containing 470 drug-event pairs (10 drugs and 47 laboratory abnormalities). The second dataset was created using the VUMC EMRs, containing 378 drug-event pairs (9 drugs and 42 laboratory abnormalities). After evaluation, CHI, ROR, PRR, and YULE all had the same F score (62%). When the reference standard of Yoon et al was used, ROR had the best F score of 68%, with 77% precision and 61% recall. The study was published in the May 2013 issue of the Journal of American Medical Informatics Association.

“Medication safety requires that each drug be monitored throughout its market life as early detection of adverse drug reactions can lead to alerts that prevent patient harm,” said lead author computer scientist Mei Liu, PhD. “EMRs have created an unprecedented resource for observational studies since they contain not only detailed patient information, but also large amounts of longitudinal clinical data.”

Pharmacovigilance is the pharmacological science relating to the collection, detection, assessment, monitoring, and prevention of ADRs, which are defined as any response to a drug, which is noxious and unintended, including lack of efficacy, which occurs at doses normally used for the prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function. ADRs are one of the major causes for failure in drug development, and severe ADRs that go undetected until the postmarketing phase of a drug often lead to patient morbidity, as exemplified by numerous drug withdrawals.

Related Links:

New Jersey Institute of Technology



view channel
Image: Micrograph showing immunofluorescence of skin differentiation markers for basal keratinocytes (Photo courtesy of Dr. Russ Carstens, University of Pennsylvania).

Alternate Splicing Proteins Critically Linked to Skin and Organ Development

Two proteins that regulate alternative splicing in epithelial cells have been linked to the proper development of the skin and protective layers that surround other organs in the body. Two steps are... Read more

Drug Discovery

view channel
Image: Use of catchphrase terms like “breakthrough” and “promising” in public news media presenting new drugs tends to result in incorrect assumptions and conclusions about the meaning and significance of criteria for FDA breakthrough-designated and accelerated-approval drugs (Photo courtesy of Dartmouth Institute).

Words That Inappropriately Enhance Perception of New Drug’s Effectiveness

Researchers have found that using the words “breakthrough” and “promising” in presenting a new drug to the general public often has a dramatic effect on judgment about its effectiveness.... Read more

Lab Technologies

view channel

New Genomic Research Kit Simplifies Exome Studies

An exciting new tool is now available for biotech researchers working in the field of genomic analysis. The human exome is critical to our genetic make-up and is generally accepted as having the greatest influence on how the genetic blueprint is utilized. The exome is defined as all coding exons in the genome and is... Read more


view channel

Collaboration Agreement to Boost Discovery of Fully Human Antibodies for Therapeutic Use

The discovery of fully human antibodies for therapeutic use will be boosted by a recently announced collaboration between a major university research center and a dynamic biopharmaceutical development company. Regeneron Pharmaceuticals, Inc. (Tarrytown, New York, USA) and The Experimental Therapeutics Institute (ETI)... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.